Table 2.
Assay | Throughputa |
EEb | SMc | Referenced | ||
---|---|---|---|---|---|---|
L | M | H | ||||
Agar Plate Assays | ||||||
CAMP test | ✓ | Elek and Levy (1950) | ||||
β-hemolytic disk assay for δ-hemolysin | ✓ | Schweizer et al. (2011) | ||||
Phospholipase plate assay | ✓ | Kouker and Jaeger (1987); Laabei et al. (2014) | ||||
Agar plate X-GAL test | ✓ | Nielsen et al. (2010) | ||||
Cell culture and ex vivo techniques | ||||||
Bacterial survival with neutrophils | ✓ | ✓ | Schwartz et al. (2009); Pang et al. (2010), White et al. (2014) | |||
Human neutrophil lysis test | ✓ | ✓ | ✓ | Nielsen et al. (2014) | ||
Human keratinocyte cell lysis test | ✓ | ✓ | ✓ | Cech et al. (2012) | ||
Rabbit erythrocyte lysis test | ✓ | ✓ | ✓ | Pang et al. (2010) | ||
Virulence expression on reconstituted human epithelia | ✓ | ✓ | Paniagua-Contreras et al. (2014) | |||
Chromatography tools | ||||||
HPLC quantification of δ-hemolysin | ✓ | ✓ | ✓ | ✓ | Otto and Gotz (2000); Quave et al. (2011) | |
LC-MS detection of δ-hemolysin | ✓ | ✓ | Somerville et al. (2003) | |||
MALDI-TOF/TOF MS detection of δ-hemolysin | ✓ | ✓ | Gagnaire et al. (2012) | |||
HPLC quantification of PSM-α | ✓ | ✓ | ✓ | Chua et al. (2014) | ||
IMS and MALDI-MS/MS characterization of metabolic products and PSMs | ✓ | ✓ | ✓ | Gonzalez et al. (2012) | ||
Quantification of extracellular AIPs by UHPLC/MS | ✓ | ✓ | ✓ | Junio et al. (2013); Roux et al. (2014) | ||
Molecular techniques | ||||||
Transcriptional analyses by Northern blotting | ✓ | ✓ | ✓ | Gagnaire et al. (2012); Nielsen et al. (2014) | ||
qRT-PCR | ✓ | ✓ | Park et al. (2007) | |||
agr::P3 driven GFP reporter assay | ✓ | ✓ | ✓ | ✓ | Murray et al. (2014); Sully et al. (2014) | |
agr::P3 driven lux reporter assay | ✓ | ✓ | ✓ | ✓ | Subrt et al. (2011); Figueroa et al. (2014) | |
P3-blaZ reporter | ✓ | ✓ | ✓ | Nielsen et al. (2014) | ||
AIP fluorescent reporter competition assay | ✓ | ✓ | Kavanaugh et al. (2007); Malone et al. (2007) | |||
Vesicle lysis test | ✓ | ✓ | Laabei et al. (2014) |
aTesting throughput: Assay is amenable to the following throughput testing. L, low throughput testing, amenable to a small number of samples. M, medium throughput screening, amenable to 96-well plate assays and not requiring robotic liquid handling systems. H, high throughput screening, amenable to large samples, such as 96-well or 384-well microtiter plates with the assistance of robotics.
bEE: Requires the use of expensive equipment or core services, such as microplate readers, HPLC, mass spectrometer, and etc.
cSM: Adapted for testing small molecule inhibitors of the agr system.
dReferences: Select references are included and this does not represent the full body of literature for each assay.